The 4 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 1.50, with a high estimate of 2.00 and a low estimate of 0.50. The median estimate represents a +106.04% increase from the last price of 0.73.
The current consensus among 4 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since September, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.08
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.